Encompass Health (EHC) fundamentals: P/E, valuation, undervalued?
Encompass Health · Health Care · ref. ETF XLV · price $124.33
In short — Encompass Health trades at 20.8× earnings (P/E), 18.6× forward, with a net margin of 10.0 % and revenue growth of +10 %. Read: Fairly valued (P/E 19 in line with ~11% growth (PEG 1.7)).
Is Encompass Health stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$124.33+1.1% over range
Oct 14, 25low $93.83 · high $127.18Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 4 analysts
Valuation : Fairly valued — P/E 19 in line with ~11% growth (PEG 1.7)
Valuation
20.8
P/E (price/earnings)
18.6
Forward P/E
1.93
PEG
4.7
Price/book (P/B)
$12.3B
Market cap
5.98
EPS
Profitability & growth
10.0 %
Net margin
+10 %
Revenue growth
+11 %
Earnings growth
$2.8B
Total debt
Encompass Health income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $4.3B | $271M | 6.2 % |
| 2023 | $4.8B | $352M | 7.3 % |
| 2024 | $5.4B | $456M | 8.5 % |
| 2025 | $5.9B | $566M | 9.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Encompass Health's P/E and is the stock undervalued? What's a good P/E?
Encompass Health's P/E is 20.8 (forward 18.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Encompass Health profitable?
Encompass Health has a net margin of 10.0 % (EPS 5.98). The company is profitable.
Is EHC stock expensive?
Our read: "Fairly valued" — P/E 19 in line with ~11% growth (PEG 1.7). Cross-check with growth and sector.
💬 A question about Encompass Health? The JPI assistant answers using our backtest data.
Keep exploring Encompass Health